The Vioxx recall case and comments

Competitiveness Review

Volumn 19, Issue 2, 2009, Pages 114-118

  Tong, Carl H ^a   Tong, Lee Ing ^b   Tong, James E ^c  

^a RADFORD UNIVERSITY   (United States)

^b NATIONAL CHIAO TUNG UNIVERSITY   (Taiwan)

^c Vanguard Group Inc   (United States)

Author keywords

Drugs; Ethics; Pharmaceuticals industry; Product safety; Profit maximization; Social responsibility; United States of America

Indexed keywords

EID: 84905465181     PISSN: None     EISSN: 20513143     Source Type: Journal    
DOI: 10.1108/10595420910942289     Document Type: Article

References (15)

1. Bovee, C.L., Houston, M.J. and Thill, J.V. (1995), Marketing, McGraw-Hill, New York, NY, p. 58.
2. Gilmartin, R. (2005), “A letter to Merck’s colleagues (regarding The Merck Code of Conduct, Our Values and Standards)”, available at: www.merck.com/about/cr/policies_performance/pdf/code_of_conduct.pdf (accessed June 3, 2005).
3. Jack, A. (2005), “Scientist vows to expose ill-effects of Vioxx”, available at: www.ft.com/cms/s/5c6a79c0-5d2b-11d9-bb9c-00000e2511c8.ft_acl=.s01=1.html (accessed January 3, 2005).
4. Jackson, I.A. and Nelson, J. (2004), Profits with Principles, Doubleday, New York, NY.
5. Kerin, R.A., Hartley, S.W., Berkowitz, E.N. and Rudelius, W. (2006), Marketing, McGraw-Hill, New York, NY, pp. 101-2.
6. Martinez, B. (2004), “Vioxx lawsuits may focus on FDA warning in 2001”, The Wall Street Journal, October 5, p. B1.
7. Mathews, A.W. and Martinez, B. (2004), “Warning signs: e-mails suggest Merck knew Vioxx’s dangers at early stage - as heart-risk evidence rose, officials played hardball; internal message: ‘Dodge!’ - company says ‘out of context’”, The Wall Street Journal, November 1, p. A1.
8. Merck & Co., Inc. (2004), “Merck announces voluntary world-wide withdrawal of Vioxx”, September 30, available at: www.vioxx.com/rofecoxib/vioxx/consumer/index.jsp (accessed January 1, 2005).
9. Merck & Co., Inc. (2005a), “Chairman’s message”, Annual Report 2004, February 22, available at: www.merck.com/finance/annualreport/ar2004/chairmans_message/ (accessed June 3,2005).
10. Merck & Co., Inc. (2005b), “The Merck code of conduct, our values and standards”, available at: www.merck.com/about/cr/policies_performance/pdf/code_of_conduct.pdf (accessed June 3, 2005).
11. Nossiter, A. (2005), “Tens of thousands of cases seen over Vioxx”, available at: www.news.yahoo.com/s/ap/20050523/ap_on_bi_ge/vioxx_hearing:_v1t=Am3H4woF9gK.z11hll1Hdlms0NUE:_y1u=X3oDMTA2bXJyZDl0BHNlYwNobA (accessed May 23,2005).
12. Reuters (2005), “Merck hid Vioxx dangers for a decade - lawyer”, available at: http://newsyahoo.com/s/nm/20050817/ts_nm/merck_vioxx_dc (accessed August 17, 2005).
13. Simmons, J. and Stipp, D. (2004), “Will Merck survive Vioxx?”, Fortune, November 1, pp. 90-104.
14. Tong, H. (1986), Learning from Forty Inspiring Business Successes, Professional Publishing Co., Radford, VA, p. 230.
15. Topol, E.J. (2004), “Correspondence - rofecoxib, Merck, and the FDA”, The New England Journal of Medicine, No. 27, pp. 2875-8.